# 1988
# Journal of Cardiopulmonary Rehabilitation
# Author Index


Abinader EG, 324
Acker JE Jr, 297
Ades PA, 141
Amplatz K, 319
Amsterdam EA, 9, 116
Andersen B, 449
Angelillo VA, 232, 449
Asmus RM, 435
Avery KE, 69

Baardman T, 265
Bahler RC, 207
Bailey KR, 518
Baird C, 326
Becker N, 149
Bedynek, JL, 371
Bell CW, 449
Ben-Ari E, 249
Bernitz H, 108
Bickford LS, 473
Blood SM, 141
Blümchen G, 171, 341
Blumenthal JA, 183, 513
Bove AA, 518
Brower RW, 265

Caldwell L, 50
Campbell JC, 449
Caston AL, 58
Charest J, 99
Christlieb I, 178
Chun DS, 303
Cilliers JF, 108
Cleeman JI, 131
Connors GA, 435
Coplan NL, 33, 270
Corriveau ML, 303
Crosby LH, 178

Delage F, 99
DePace NL, 94
Dewan NA, 449
Diethrich EB, 285
Dolan GF, 303
Doyle P, 492
Drory Y, 249

Elkousy NM, 492
Emery CF, 183
Esterbrooks DJ, 232

Fernhall, B, 360
Fieselman CC, 69
Finkelhor RS, 207
Fioretti P, 265
Fisman EZ, 249
Fogland TL, 232
Foto M, 492
Fraser GE, 50
Fredrikson M, 513
Friedman BA, 249
Froelicher VF, 357, 505

Gavish A, 507
Gertz EW, 331
Gleim GW, 33, 270
Goldhammer E, 324
Gordon NF, 108
Graves JE, 134

Hanson P, 28
Härkönen M, 254
Harris CM, 303
Haslam DRS, 213
Hassan A, 324
Heng MK, 58
Hiatt WR, 525
Hill NS, 462
Hodgkin JE, 423, 435, 473
Hoffmann JJ, 58
Holland GJ, 58
Holly RG, 9
Holly T, 270
Hopp JW, 439
Hossack KF, 525
Hugenholtz PG, 265

Jelinek M, 149
Jetté M, 171, 341
Jobin J, 99
Johnson K, 50

Kahn, M, 453
Karch, R, 371
Karnegis JN, 319
Kelemen MH, 292
Keller C, 303
Kellermann JJ, 249
Keren A, 507
Kirby TE, 45
Koivula T, 254
Komorowski D, 492
Krantz, DS, 371
Kubo C, 50
Kukkonen-Harjula K, 254

Labuhn KT, 326
LaClair L, 50
Lamont LS, 207
Landry F, 171, 341
Laslett L, 116
Leblanc M-H, 99
Lee GG, 50
Lehnhard HJ, 45
Lehnhard RA, 45
Lemole G, 94
Lenfant C, 131
Lui H, 9

MacDougall JD, 213
Malouf S, 324
Marin JJ, 58
Martin D, 297
Marttinen A, 254
Mason M, 292
Mattison S, 50
Matts JP, 319
Mayers MM, 58
McCartney N, 213
McDonald I, 149
McKelvie RS, 213
McMurray RG, 69
Medeiros M, 285
Michelis MF, 33
Miltenberger LA, 134
Muir WW, 45
Myburgh DP, 108

Nash DT, 18
Nawaz D, 525
Neese RA, 331
Neish CM, 439
Neutel JM, 108
Nicholas JA, 33, 270

O'Donohue WJ Jr, 449
O'Malley J, 453
Osterhues DJ, 9

Parr GVS, 94
Paumer L, 116
Petratis MM, 232
Pines A, 249
Plowman, SA, 360
Pollock ML, 134
Powell A, 149

Reese SS, 58
Regensteiner JG, 525
Rejeski WJ, 183
Rogers PJ, 518
Rubenfire M, 226
Rutledge JC, 116
Ryschon KL, 232

Sagiv M, 134
Santorelli CG, 207
Sassenrath EN, 9
Scandura M, 270
Schaeffer MA, 371
Schneider LE, 50
Schram V, 28
Seelaus PA, 94
Sheps DS, 69
Sidney K, 171
Skinner JS, 285
Smith LK, 285
Sneider R, 453
Spagna P, 94
Squires RW, 518
Stanley WC, 331
Stern S, 507
Stewart KJ, 292
Szymanski LM, 360

Tessier Y, 99
Tiep BL, 442
Tremblay GJL, 99
Tuna N, 319
Tzivoni D, 507

Villa I, 99
Vincent WJ, 58
Vuori I, 254

Walling A, 99
Weber F, 58
Weintraub WS, 94
Weiss, SM, 371
Weisz G, 507
Welch MA Jr, 492
Williams MA, 232
Wisneski JA, 331
Wood KL, 178
Wrisley D, 226

Yaney, SF, 371

Zabetakis PM, 33
Zoltick, JM, 371
Zwiers G, 265

# 1988
# Journal of Cardiopulmonary Rehabilitation
# Author Index


Abinader EG, 324
Acker JE Jr, 297
Ades PA, 141
Amplatz K, 319
Amsterdam EA, 9, 116
Andersen B, 449
Angelillo VA, 232, 449
Asmus RM, 435
Avery KE, 69

Baardman T, 265
Bahler RC, 207
Bailey KR, 518
Baird C, 326
Becker N, 149
Bedynek, JL, 371
Bell CW, 449
Ben-Ari E, 249
Bernitz H, 108
Bickford LS, 473
Blood SM, 141
Blümchen G, 171, 341
Blumenthal JA, 183, 513
Bove AA, 518
Brower RW, 265

Caldwell L, 50
Campbell JC, 449
Caston AL, 58
Charest J, 99
Christlieb I, 178
Chun DS, 303
Cilliers JF, 108
Cleeman JI, 131
Connors GA, 435
Coplan NL, 33, 270
Corriveau ML, 303
Crosby LH, 178

Delage F, 99
DePace NL, 94
Dewan NA, 449
Diethrich EB, 285
Dolan GF, 303
Doyle P, 492
Drory Y, 249

Elkousy NM, 492
Emery CF, 183
Esterbrooks DJ, 232

Fernhall, B, 360
Fieselman CC, 69
Finkelhor RS, 207
Fioretti P, 265
Fisman EZ, 249
Fogland TL, 232
Foto M, 492
Fraser GE, 50
Fredrikson M, 513
Friedman BA, 249
Froelicher VF, 357, 505

Gavish A, 507
Gertz EW, 331
Gleim GW, 33, 270
Goldhammer E, 324
Gordon NF, 108
Graves JE, 134

Hanson P, 28
Härkönen M, 254
Harris CM, 303
Haslam DRS, 213
Hassan A, 324
Heng MK, 58
Hiatt WR, 525
Hill NS, 462
Hodgkin JE, 423, 435, 473
Hoffmann JJ, 58
Holland GJ, 58
Holly RG, 9
Holly T, 270
Hopp JW, 439
Hossack KF, 525
Hugenholtz PG, 265

Jelinek M, 149
Jetté M, 171, 341
Jobin J, 99
Johnson K, 50

Kahn, M, 453
Karch, R, 371
Karnegis JN, 319
Kelemen MH, 292
Keller C, 303
Kellermann JJ, 249
Keren A, 507
Kirby TE, 45
Koivula T, 254
Komorowski D, 492
Krantz, DS, 371
Kubo C, 50
Kukkonen-Harjula K, 254

Labuhn KT, 326
LaClair L, 50
Lamont LS, 207
Landry F, 171, 341
Laslett L, 116
Leblanc M-H, 99
Lee GG, 50
Lehnhard HJ, 45
Lehnhard RA, 45
Lemole G, 94
Lenfant C, 131
Lui H, 9

MacDougall JD, 213
Malouf S, 324
Marin JJ, 58
Martin D, 297
Marttinen A, 254
Mason M, 292
Mattison S, 50
Matts JP, 319
Mayers MM, 58
McCartney N, 213
McDonald I, 149
McKelvie RS, 213
McMurray RG, 69
Medeiros M, 285
Michelis MF, 33
Miltenberger LA, 134
Muir WW, 45
Myburgh DP, 108

Nash DT, 18
Nawaz D, 525
Neese RA, 331
Neish CM, 439
Neutel JM, 108
Nicholas JA, 33, 270

O'Donohue WJ Jr, 449
O'Malley J, 453
Osterhues DJ, 9

Parr GVS, 94
Paumer L, 116
Petratis MM, 232
Pines A, 249
Plowman, SA, 360
Pollock ML, 134
Powell A, 149

Reese SS, 58
Regensteiner JG, 525
Rejeski WJ, 183
Rogers PJ, 518
Rubenfire M, 226
Rutledge JC, 116
Ryschon KL, 232

Sagiv M, 134
Santorelli CG, 207
Sassenrath EN, 9
Scandura M, 270
Schaeffer MA, 371
Schneider LE, 50
Schram V, 28
Seelaus PA, 94
Sheps DS, 69
Sidney K, 171
Skinner JS, 285
Smith LK, 285
Sneider R, 453
Spagna P, 94
Squires RW, 518
Stanley WC, 331
Stern S, 507
Stewart KJ, 292
Szymanski LM, 360

Tessier Y, 99
Tiep BL, 442
Tremblay GJL, 99
Tuna N, 319
Tzivoni D, 507

Villa I, 99
Vincent WJ, 58
Vuori I, 254

Walling A, 99
Weber F, 58
Weintraub WS, 94
Weiss, SM, 371
Weisz G, 507
Welch MA Jr, 492
Williams MA, 232
Wisneski JA, 331
Wood KL, 178
Wrisley D, 226

Yaney, SF, 371

Zabetakis PM, 33
Zoltick, JM, 371
Zwiers G, 265

# 1988
# Journal of Cardiopulmonary Rehabilitation
# Subject Index


**β-Adrenergic blockade.** *See* Beta-blockers
**Aerobic capacity,** prediction with Naughton treadmill protocol, 297–302
**Aerobic fitness test,** Canadian, blood pressure response to, 171–176
**American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)**
abstracts of third annual meeting, 391–412
editorials, 357–358, 505–506
issues in reimbursement for cardiac rehabilitation, 276–278
survey of pulmonary rehabilitation programs, 473–491
**American Association for Respiratory Care (AARC),** survey of pulmonary rehabilitation programs, 473–491
**American College of Cardiology,** abstracts of 1988 annual meeting, 194–195
**American Heart Association,** abstracts of 60th scientific sessions, 26–27
**Aneurysm resection,** left ventricular, exercise training after, 178–180
**Angina pectoris**
compared to silent ischemia in exercise testing, 507–512
diltiazem and nitrates in, 285–291
gallopamil in, 249–253
postinfarction, prognosis after medical or surgical therapy, 94–98
**Antihypertensive agents**
affecting carbohydrate and lipid metabolism, 18–23
affecting exercise performance, 108–115
efficacy at rest and during exercise, 116–122
**Arm ergometry,** and rate-pressure product relation to oxygen consumption, 270–274
**Arrhythmias,** and ventricular asystole with syncope in mitral valve prolapse, 324–325
**Asystole,** ventricular, in mitral valve prolapse, 324–325
**Atenolol**
affecting carbohydrate and lipid metabolism, 18–23
and exercise performance, 108–115

**Behavioral interventions in cardiac disease**
occupation-based, 371–377
office-based approach to, 50–57
**Beta-blockers**
affecting carbohydrate and lipid metabolism, 18–23
affecting exercise performance, 108–115
efficacy of propranolol at rest and during exercise, 116–122
and exercise conditioning in coronary patients, 141–143
**Bicycle exercise**
air-braked ergometer in, 207–211
antihypertensive therapy affecting, 108–115
and effects of gallopamil in angina pectoris, 249–253
in five-year follow-up of uncomplicated infarction, 149–153
hyperkalemia in, 33–37
lactate metabolism in, 331–338
performance in smokers, 326–329
in predischarge evaluation after infarction, 265–269
program in West Germany, 341–349
in pulmonary rehabilitation at Eisenhower Medical Center, 453–461
and rate-pressure product relation to oxygen consumption, 270–274
and responses to local cold applications, 9–15
and syncope ventricular asystole in mitral valve prolapse, 324–325
in water, 69–74
**Blood pressure.** *See also* Hypertension
direct measurements during weightlifting, 213–225
exaggerated response to exercise, 171–176
in exercise tests in peripheral vascular disease, 525–532
graded exercise testing affecting, 360–369
rate-pressure product relation to oxygen consumption in exercise modalities, 270–274
responses to cold pressor test in exercise, 518–524
**Book and audiovisual reviews,** 80, 123–125, 162, 279–280, 358
**Bronchodilators in pulmonary rehabilitation,** 429

**Calcium channel blockers**
diltiazem with nitrates in angina, 285–291
gallopamil in angina pectoris, 249–253
and skeletal muscle function, 45–48
**Canada**
aerobic fitness test, blood pressure response to, 171–175
consensus on exercise, 505–506
**Captopril,** and exercise performance, 108–115
**Carbohydrate metabolism,** antihypertensive drugs affecting, 18–23
**Catecholamines**
plasma levels in stress, and elevated blood lipids, 513–517
urinary excretion of, exercise training affecting, 9–15
**Cholesterol levels**
and catecholamine responses to stress, C1–C4
and ineffectiveness of dietary counseling, 226–230
and National Cholesterol Education Program, 131–133
**Circuit weight training,** effects of, 292–296
**Claudication,** intermittent, and evaluation of exercise performance, 525–532
**Clonidine,** efficacy at rest and during exercise, 116–122
**Cold**
localized exposure to, and responses after exercise training, 9–15
pressor test in exercise, cardiovascular responses to, 518–524
**Coronary artery disease**
bypass graft surgery in, and prognosis with postinfarction angina, 94–98
exercise testing in. *See* Exercise testing
infarction with. *See* Myocardial infarction
**Counseling**
behavioral, as Type A intervention, 371–377
dietary, in hypercholesterolemia, ineffectiveness of, 226–230
in office-based behavioral interventions, 50–57

**Diet**
and behavioral interventions from office setting, 50–57
counseling in hypercholesterolemia, ineffectiveness of, 226–230
**Diltiazem**
nitrates with, in angina, 285–291
and skeletal muscle function, 45–48

**Editorials,** 357–358, 505–506
**Educational programs in pulmonary rehabilitation,** 439–441
**Eisenhower Medical Center program for pulmonary rehabilitation,** 453–461
**Electrocardiography**
postinfarction loss of Minnesota Q-QS complex, 319–323
R-wave amplitude in graded exercise testing, 360–369
silent and symptomatic exercise-induced ST depression, 507–512
**Ergometry.** *See* Exercise testing
**Erratum,** 162, 533
**Erythrocyte insulin receptors in prolonged exercise,** 254–259
**Exercise**
and behavioral interventions from office setting, 50–57
capacity after pulmonary rehabilitation, 303–308
continuous ECG monitoring in, and reimbursement by health insurers, 276–278
and muscle function affected by calcium antagonists, 45–48
potassium levels in, 33–37
prolonged, erythrocyte insulin receptors in, 254–259
**Exercise testing**
air-braked ergometry in, 207–211
antihypertensive agents affecting performance in, 108–115
and effects of hand-held and wrist weights in

hypertension, 134–140
and effects of diltiazem and nitrates in angina, 285–291
and efficacy of antihypertensive therapy, 116–122
exaggerated blood pressure response to, in hypertension, 171–176
in five-year follow-up of uncomplicated infarction, 149–153
graded testing affecting blood pressure, 360–369
lactate metabolism in, 331–338
performance evaluation in peripheral vascular disease, 525–532
performance in smokers, 326–329
and prediction of aerobic capacity, 297–302
and rate-pressure product relation to oxygen consumption in four modalities, 270–274
rowing ergometry compared to treadmill exercise, 232–237
silent and symptomatic ischemia in, 507–512
steptreadmill ergometer compared to treadmill protocol, 58–67
and syncope with ventricular asystole in mitral valve prolapse, 324–325
transtracheal oxygen therapy affecting, 449–452
in water, 69–74
**Exercise training**
approaches in Germany and U.S., 357–358
and arterial pressure measurements during weightlifting, 213–225
Canadian consensus on, 505–506
and cardiovascular responses to cold pressor test, 518–524
and effects of beta-blockers on training response, 141–143
effects of circuit weight training, 292–296
after left ventricular aneurysm resection, 178–180
and postinfarction rehabilitation, 99–105
and predischarge working capacity after infarction, 265–269
program in West Germany, 341–349
and psychosocial functioning after infarction, 183–192
in pulmonary rehabilitation, 431
at Eisenhower Medical Center, 453–461
and response to localized cold, 9–15
and Type A stress reduction in occupational setting, 371–377
weight-loaded walking in, 28–32

**Gallopamil in angina pectoris,** 249–253
**Germany**
approach to rehabilitation compared to U.S., 357–358
cardiac rehabilitation in Klinik Roderbirken, 341–349

**Health insurance**
and reimbursement for cardiac rehabilitation, 276–278
and reimbursement for pulmonary rehabilitation, 492–497
**Hemodynamic measurements**
in acute phase of myocardial infarction, 265–269
diltiazem and nitrates affecting, in angina, 285–291
direct blood pressure measurements during weight lifting, 213–225
during exercise in water, 69–74
and exaggerated blood pressure response to exercise in hypertension, 171–176
in exercise with hand-held and wrist weights in hypertension, 134–140
in exercise tests in peripheral vascular disease, 525–532
in graded exercise testing, 360–369
and potassium levels during exercise, 33–37
and rate-pressure product relation to oxygen consumption in exercise modalities, 270–274
in responses to local cold application, 9–15
in rowing ergometry vs. treadmill exercise, 232–237
in weight-loaded walking, 28–32
**Home care for ventilator-assisted patients,** 462–477
**Hydralazine,** efficacy at rest and during exercise, 116–122
**Hydrochlorothiazide**
affecting carbohydrate and lipid metabolism, 18–23
efficacy at rest and during exercise, 116–122
and exercise performance, 108–115
**Hypertension**
drugs in. *See* Antihypertensive agents
and exaggerated blood pressure response to exercise, 171–176
exercise with hand-held and wrist weights in, 134–140
graded exercise testing in, 360–369

**In the literature,** 26–27, 155–159, 194–195, 238–241, 310–311, 378–382
**Infarction.** *See* Myocardial infarction
**Insulin receptors,** erythrocyte, in prolonged exercise, 254–259

**Lactate**
concentrations with exercise in peripheral vascular disease, 525–532
metabolism during exercise, 331–338
threshold for, and hyperkalemia during exercise, 33–37
**Letters to the editor,** 7–8, 76–78, 160–161
**Lipids**
metabolism affected by antihypertensive drugs, 18–23
plasma levels related to neuroendocrine and cardiovascular responses to stress, 513–517
**Lung disease.** *See also* Pulmonary rehabilitation and home care for ventilator-assisted patients, 462–477

**Metabolism**
carbohydrate and lipid, antihypertensive drugs affecting, 18–23
lactate, during exercise, 331–339
responses in weight-loaded walking, 28–32
**Minnesota Q-QS codes,** postinfarction loss of, 319–323
**Mitral valve prolapse,** syncope and ventricular asystole in, 324–325
**Muscle**
calcium antagonists affecting, 45–48
strength after circuit weight training, 292–296
**Myocardial infarction**
exercise testing after. *See* Exercise testing
hemodynamic measurements in acute phase, 265–269
and lipid levels related to responses in stress, 513–517
and loss of ECG Minnesota Q-QS codes, 319–323
prognosis of postinfarction angina, 94–98
rehabilitation potential of postinfarction patients, 99–105
uncomplicated, five-year follow-up of, 149–153

**Nadolol,** and exercise performance, 108–115
**National Cholesterol Education Program,** 131–133
**Naughton treadmill protocol,** and prediction of aerobic capacity, 297–302
**Neuroendocrine responses to stress,** and lipid status, 513–517
**New product releases,** 40, 83, 198–201
**Nifedipine,** and skeletal muscle function, 45–48
**Nitrates,** diltiazem with, in angina, 285–291

**Occupational settings,** and interventions in Type A behavior, 371–377
**Occupational therapy in pulmonary rehabilitation,** 431
**Office-based approach to behavior interventions in cardiac disease,** 50–57
**Oxygen consumption**
and exercise capacity after pulmonary rehabilitation, 303–308
in exercise tests in peripheral vascular disease, 525–532
and rate-pressure product in exercise modalities, 270–274
**Oxygen therapy**
continuous flow in, 444
electronic-demand devices in, 446
portable systems in, 443–444
in pulmonary rehabilitation, 429–430
for mobile patients, 442–447
reservoir cannulas in, 445–446
transtracheal, 444–445
affecting exercise capacity, 449–452

**Pacemaker therapy,** in ventricular asystole with syncope in mitral valve prolapse, 324–325
**Physical therapy in pulmonary rehabilitation,** 430–431
**Potassium levels in progressive dynamic exercise,** 33–37
**Propranolol**
affecting carbohydrate and lipid metabolism, 18–23
efficacy at rest and during exercise, 116–122
**Psychosocial function**
and occupation-based Type A interventions, 371–377
postinfarction, exercise training affecting, 183–192
in pulmonary rehabilitation, 431
**Pulmonary rehabilitation**
educational methods in, 439–441
exercise capacity after, 303–308
and guidelines for reimbursement, 492–497
initial assessment in, 435–438
national survey of, 473–491
oxygen therapy in, 429–430. *See also* Oxygen therapy structure and benefits of, 423–434
trends in Eisenhower Medical Center, 453–461

**Q-QS codes,** Minnesota, postinfarction loss of, 319–323

**Reimbursement**
for cardiac rehabilitation, 276–278
for pulmonary rehabilitation, 492–497
**Respiratory therapy in pulmonary rehabilitation,** 429–430
**Roderbirken Klinik,** cardiac rehabilitation in, 341–349
**Rowing exercise**
compared to treadmill exercise, 232–237
lactate metabolism in, 331–338
and rate-pressure product relation to oxygen consumption, 270–274
**Running,** prolonged, and changes in erythrocyte insulin receptors, 254–259

**Smokers,** attitudes and exercise performance during cardiac rehabilitation, 326–329
**ST depression,** exercise-induced, silent or symptomatic, 507–512
**Stress**
management with Type A interventions in occupational setting, 371–377
neuroendocrine and cardiovascular responses to, and lipid status, 513–517
**Swimming program in West Germany,** 341–349
**Syncope with ventricular asystole,** in mitral

valve prolapse, 324–325

**Tracheostomy,** positive-pressure ventilation through, 467–468
**Treadmill exercise**
antihypertension therapy affecting, 116–122
compared to rowing ergometry, 232–237
conventional mode compared to steptreadmill ergometry, 58–67
and effects of diltiazem and nitrates in angina, 285–291
hand-held and wrist weights in, in hypertension, 134–140
performance evaluation in peripheral vascular disease, 525–532
postinfarction, and rehabilitation potential, 99–105
and prediction of aerobic capacity, 297–302
in pulmonary rehabilitation at Eisenhower Medical Center, 453–461
and rate-pressure product relation to oxygen consumption, 270–274
silent and symptomatic ischemia in, 507–512
transtracheal oxygen therapy affecting, 449–452
weight-loaded, responses to, 28–32
**Type A interventions,** occupation-based, 371–377

**Ventilator-assisted patients,** home care of, 462–477
**Ventricles,** cardiac
aneurysm resection in, exercise training after, 178–180
asystole with syncope in mitral valve prolapse, 324–325
function with postinfarction loss of ECG Minnesota Q-QS codes, 319–323
**Verapamil,** and skeletal muscle function, 45–48

**Walking**
program in West Germany, 341–349
prolonged, and changes in erythrocyte insulin receptors, 254–259
treadmill. *See* Treadmill exercise
weight-loaded, responses to, 28–32
**Water immersion,** exercise testing in, 69–74
**Weightlifting**
and arterial pressure measurements in cardiac patients, 213–225
effects of circuit weight training, 292–296
after left ventricular aneurysm resection, 178–180
**Weight-loaded walking,** responses to, 28–32
**Weights,** hand-held and wrist, in exercise in hypertension, 134–140
**Women,** prognosis with postinfarction rehabilitation program, 99–105

## Erratum

In the October 20, 1988 issue for the article by Szymanski, Fernhall, and Plowman (J Cardiopulmonary Rehabil 1988;8:360–370) the following correction should be noted: the first sentence under Introduction should read, "The ST-segment has been the most commonly evaluated electrocardiographic (ECG) parameter indicative of myocardial ischemia during a graded exercise test (GXT).[1]" The words "sinus tachycardia" were incorrectly inserted.